NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the market closed on Tuesday that its third-quarter revenues rose 4 percent driven by strong clinical diagnostics sales.

The firm reported total revenues of $461.1 million for the three-month period ended Sept. 30, compared to revenues of $441.8 million for the third quarter of 2008. On a currency-neutral basis, Bio-Rad's revenue growth for the quarter was 11 percent.

It beat analysts' consensus estimate on both the top and bottom line.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.